May 25, 2021
New Fellows
The Australian inventor of 3D-printed bone substitutes is among a group of scientists being acknowledged today for their outstanding contributions to science.
Professor Hala Zreiqat and her team developed world-first techniques for 3D-printing strong, bio-compatible ceramic materials that can bond to and help repair bones. This is leading to the development of new orthopaedic implants, including the world’s first synthetic material for healing large areas of bone while supporting weight.
The Jordanian migrant who came to Australia in 1991 to pursue her dream of medical research is one of 22 scientists newly elected a Fellow of the Australian Academy of Science.
Credit: The Wistar Institute
PHILADELPHIA and MELBOURNE, Australia (May. 17, 2021) A team of scientists from The Wistar Institute in Philadelphia and the Peter MacCallum Cancer Center in Melbourne, Australia, discovered a new checkpoint mechanism that fine-tunes gene transcription. As reported in a study published in
Cell, a component of the Integrator protein complex tethers the protein phosphatase 2A (PP2A) to the site of transcription allowing it to stop the activity of the RNA polymerase II enzyme (RNAPII). Disruption of this mechanism leads to unrestricted gene transcription and is implicated in cancer.
The study points to new viable opportunities for therapeutic intervention demonstrating the anti-cancer effect of a new combination treatment in preclinical models of solid and hematopoietic malignancies.
New CAR T Approach Clears Brain Cancer Tumors in Preclinical Models
Fluorescence labelling of distinct layers of the brain. Each color represents a different cell type within the cortex. [Maria Bergamasco, Walter and Eliza Institute of Medical Research]
May 10, 2021
Fluorescence labelling of distinct layers of the brain. Each color represents a different cell type within the cortex. [Maria Bergamasco, Walter and Eliza Institute of Medical Research]
Share
Scientists in Australia report that they used chimeric antigen receptor (CAR) T cell therapy to clear brain cancer tumors in preclinical models. The team, which published its study (“Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma”) in
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the
Date Time
Community focus on TB
The optimisation of science and practice relating to tuberculosis (TB) – the world’s oldest and deadliest pandemic – through collaboration, translation research and local solutions is the goal of a new group formed in Melbourne.
The Melbourne TB Community (MTBC) will promote collaboration among researchers, practitioners and community to strengthen local capacity and develop a coordinated and critical mass of research.
Founding committee member, Doherty Institute Principal Research Fellow, Associate Professor Sarah Dunstan said the MTBC aims to capitalise on the breadth of Melbourne’s world-class TB-related expertise.
“The MTBC is open to all involved in TB-related science and practice around Melbourne